Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Basic Understanding About Graves’ Disease
source: American Thyroid Association
year: 2019
summary/abstract:What Is Graves’ Disease?
Graves’ disease is an autoimmune disease that leads to a generalized overactivity of the entire thyroid gland (hyperthyroidism). It is the most common cause of hyperthyroidism in the United States. It is named after Robert Graves, an Irish physician, who described this form of hyperthyroidism about 150 years ago. It is 7-8 times more common in women than men.
What Causes Graves’ Disease?
Graves’ disease is triggered by a process in the body’s immune system, which normally protects us from foreign invaders such as bacteria and viruses. The immune system destroys foreign invaders with substances called antibodies produced by blood cells known as lymphocytes. Sometimes the immune system can be tricked into making antibodies that cross-react with proteins on our own cells. In many cases these antibodies can cause destruction of those cells. In Graves’ disease these antibodies (called the thyrotropin receptor antibodies (TRAb) or thyroid stimulating immunoglobulins (TSI) do the opposite – they cause the cells to work overtime. The antibodies in Graves’ disease bind to receptors on the surface of thyroid cells and stimulate those cells to overproduce and release thyroid hormones. This results in an overactive thyroid (hyperthyroidism).
read more
Related Content
-
GDATF Community Conversations: Long-Term Use of Anti-Thyroid Drugshttps://www.youtube.com/watch?v=Az5B8FU7...
-
Total Thyroidectomy (Tx) Versus Thionamides (Antithyroid Drugs) in Patients With Moderate-to-Severe Graves’ Op...Background: Graves' disease (GD) is cha...
-
Teprotumumab for the Treatment of Active Thyroid Eye DiseaseBackground: Thyroid eye disease is a de...
-
Sensitivity and Responsiveness of the Patient-Reported TED-QOL to Rehabilitative Surgery in Thyroid Eye DiseaseWe tested the sensitivity and responsive...
-
The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves’ Ophthalmopathy PatientsPurpose: The purpose of this study is t...
-
Management of Fetal and Neonatal Graves’ DiseaseFetal and neonatal autoimmune hyperthyro...
-
Consensus Statement of the European Group on Graves’ Orbitopathy (EUGOGO) on Management of Graves’ Orbit...Graves’ orbitopathy (GO) constitutes a...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
myBinder